A comprehensive view of regeneron pharmaceuticals inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves Regeneron and Sanofi’s injectable Dupixent dupilumab to treat adult patients with prurigo nodularis, making it the first and only medicine specifically indicated to treat the disease; 75,000 adults in the US have prurigo nodularis
Published: September 29, 2022 by PR Newswire
US Solicitor General suggests Supreme Court turn down Amgen’s request to hear PCSK9 patent case with Sanofi and Regenron; appeals court ruling called Amgen’s claims invalid because it would take ‘undue experimentation’ to enable their full scope
Published: September 26, 2022 by FiercePharma
Regeneron and partner Alnylam Pharmaceuticals to move into Phase 2 trials with their experimental injectable liver disease drug ALN-HSD to treat nonalcoholic steatohepatitis after encouraging Phase 1 findings
Published: September 16, 2022 by SeeNews Pharmaceuticals
Morgan Stanley upgrades Regeneron to overweight, noting range of products delivering durable revenues, and advancing oncology pipeline has potential to diversify base business; company's Eylea treatment for retinal diseases also show promising results
Published: September 09, 2022 by Invezz
Use of Lilly’s bamlanivimab-etesevimab, Regeneron’s casirivimab-imdevimab COVID-19 antibodies 'widespread' after FDA ban, potentially costing US over US$70.0M; hospitals, health systems administered over158,000 doses of these mAbs in early 2022: JAMA
Published: September 02, 2022 by FiercePharma

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count